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Objectives
Despite the widespread use of PROs in RCTs evidence
suggests that results may not influence practice. Absence
of an a priori rationale for measuring PROs and poor
integration with trial clinical outcomes may contribute to
this problem. This hypothesis was addressed by examin-
ing current reporting of PROs in GI cancer RCTs.
Methods
A systematic review in MEDLINE, EMBASE and
Cochrane databases searched for RCTs of radical treat-
ments for GI cancer using validated PROMs, published
between 2000 and 2009. Trials with a potential high risk
of bias (Cochrane Collaboration tool) were excluded. Inde-
pendent data extraction (3 reviewers) recorded the ratio-
nale for PRO measurement classifying this as 1) no
rationale, 2) general rationale e.g. to examine QOL, 3) par-
tial rationale e.g. hypothesis for a specific PRO domain or
an expected direction of change or 4) complete rationale
specifying a PRO domain and direction of change. Inte-
grated reporting of clinical and PROs was investigated by
examining whether trials reported PROs with or separately
to clinical data, if PRO results were included in abstracts,
and publication dates and journal impact factors where
PRO and clinical results were published separately.
Results
43 papers reporting PROs from 40 trials were included.
Interventions were mostly chemotherapy (52.5%) and in
colorectal cancer (77.5%). 16 (37.3%) papers did not report
a PRO rationale, 14 (32.6%) gave general reasons, 6 (14.0%)
a partial reason and 7 (16.3%) provided a detailed rationale
describing hypothesised change in PRO domain and direc-
tion. Clinical and PROs were reported together in 30
papers (70.0%), in which PROs were typically a secondary
trial endpoint (27/30, 90.0%). Of these, 11 had significant
PRO results, with 10 (90.1%) reporting this in the abstract.
13 papers (30.3%) were separate reports of PRO data, sup-
plementary to clinical findings. Median time between clini-
cal and PRO publications was 21 months (range 5-51). The
median journal impact factor for clinical and PRO papers
was 15.6 and 6.3 respectively (p=0.03). Eight (61.5%) of the
corresponding clinical papers did not report any PRO data
and four (30.7%) made no indication that PROs had been
measured despite the subsequent PRO publication.
Conclusions
Few GI cancer RCTs provided a detailed rationale for
measuring PROs and integration of clinical and PRO
results was often poor. Standards for reporting PROs
alongside clinical outcomes are required to improve
clinical understanding and facilitate use of all trial data
in decision-making.
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